76
|
Urdl K, Weiss S, Hesser G, Kandelbauer A, Zikulnig-Rusch E, Müller U, Kern W. Data on production and characterization of melamine-furan-formaldehyde particles and reversible reactions thereof. Data Brief 2019; 25:104056. [PMID: 31198835 PMCID: PMC6557758 DOI: 10.1016/j.dib.2019.104056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 05/06/2019] [Accepted: 05/17/2019] [Indexed: 11/25/2022] Open
Abstract
The data present in this article affords insides in the characterization of a newly described bi-functional furan-melamine monomer, which is used for the production of monodisperse, furan-functionalized melamine-formaldehyde particles, as described in https://doi.org/10.1016/j.eurpolymj.2019.04.006 Urdl et al., 2019. In the related research article Urdl et al., 2019 data interpretations can be found. The furan-functionalization of particles is necessary to perform reversible Diels-Alder reactions with maleimide (BMI) crosslinker to form thermoreversible network systems. To understand the reaction conditions of Diels-Alder (DA) reaction with a Fu-Mel monomer and a maleimide crosslinker, model DA reaction were performed and evaluated using dynamic FT-IR measurements. During retro Diels-Alder (rDA) reactions of the monomer system, it was found out that some side reaction occurred at elevated temperatures. The data of evaluating the side reaction is described in one part of this manuscript. Additional high resolution SEM images of Fu-Mel particles are shown and thermoreversible particle networks with BMI2 are shown. The data of different Fu-Mel particle networks with maleimide crosslinker are presented. Therefore, the used maleimide crosslinker with different spacer lengths were synthesized and the resulting networks were analyzed by ATR-FT-IR, SEM and DSC.
Collapse
|
77
|
Shahswar R, Haferlach C, Walter W, Twardziok S, Hutter S, Meggendorfer M, Kern W, Haferlach T, Stengel A. PS922 BENEFITS OF RNA SEQUENCING IN DETECTING RECURRENT AND NOVEL FUSION TRANSCRIPTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000561964.61382.e6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
78
|
Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica 2019; 104:1935-1949. [PMID: 31048353 PMCID: PMC6886439 DOI: 10.3324/haematol.2019.222059] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 04/29/2019] [Indexed: 12/15/2022] Open
Abstract
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past two decades, our knowledge about the pathogenesis and molecular mechanisms in CMML has increased substantially. In parallel, better diagnostic criteria and therapeutic strategies have been developed. However, many questions remain regarding prognostication and optimal therapy. In addition, there is a need to define potential pre-phases of CMML and special CMML variants, and to separate these entities from each other and from conditions mimicking CMML. To address these unmet needs, an international consensus group met in a Working Conference in August 2018 and discussed open questions and issues around CMML, its variants, and pre-CMML conditions. The outcomes of this meeting are summarized herein and include diag nostic criteria and a proposed classification of pre-CMML conditions as well as refined minimal diagnostic criteria for classical CMML and special CMML variants, including oligomonocytic CMML and CMML associated with systemic mastocytosis. Moreover, we propose diagnostic standards and tools to distinguish between 'normal', pre-CMML and CMML entities. These criteria and standards should facilitate diagnostic and prognostic evaluations in daily practice and clinical studies in applied hematology.
Collapse
|
79
|
Hartmann L, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations. Genes Chromosomes Cancer 2019; 58:698-704. [PMID: 30994218 DOI: 10.1002/gcc.22761] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Accepted: 04/16/2019] [Indexed: 01/22/2023] Open
Abstract
Deletions in the long arm of chromosome 7 (del(7q)) are recurrent cytogenetic aberrations in myeloid neoplasms. They occur either isolated or as part of a complex karyotype and are associated with unfavorable prognosis in certain disease entities. We performed detailed cytogenetic analysis, molecular analysis, and array comparative genomic hybridization in a cohort of 81 patients with a variety of myeloid malignancies and del(7q) as sole chromosomal alteration. In 70% (57/81) of patients, we identified a commonly deleted region (size: 18 Mb) involving the genomic region 101 912.442 (7q22.1)-119 608.824 (7q31.31). Furthermore, in 80 patients, we analyzed 17 genes commonly mutated in myeloid neoplasms and identified high mutation frequencies in ASXL1 34% (27/80), TET2 33% (26/80), RUNX1 25% (20/80), DNMT3A 25% (20/80), while TP53 was rarely affected (5%, 4/80). ASXL1 and TET2 showed similar mutation frequencies across all analyzed entities while RUNX1, CBL, and JAK2 were specifically mutated in patients with acute myeloid leukemia (AML), chronic myelomonocytic leukemia, and myeloproliferative neoplasms, respectively. We detected a significantly higher frequency of RUNX1 (42% vs 13%, P = .0001) and ASXL1 (32% vs 14%, P = .008) mutations in AML patients with del(7q) compared to other AML patients in the Medical Research Council unfavorable risk group (n = 464), indicating a cooperative leukemogenic potential. Our data provide further insight into the pathomechanism of this cytogenetic subgroup.
Collapse
|
80
|
Balk B, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A. Impact of 9q deletions on the classification of patients with acute myeloid leukemia. J Cancer Res Clin Oncol 2019; 145:2871-2874. [PMID: 30927073 DOI: 10.1007/s00432-019-02908-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Accepted: 03/25/2019] [Indexed: 12/19/2022]
|
81
|
Jeromin S, Eder C, Haferlach C, Haferlach T, Kern W. Impact of assay procedures on detection of MR 4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis. Int J Lab Hematol 2019; 41:e109-e112. [PMID: 30860652 DOI: 10.1111/ijlh.13004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 01/28/2019] [Accepted: 02/18/2019] [Indexed: 11/30/2022]
|
82
|
Hartmann L, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A. Comprehensive molecular characterization of myeloid malignancies with 9q deletion. Leuk Lymphoma 2019; 60:2591-2593. [PMID: 30844315 DOI: 10.1080/10428194.2019.1585840] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
83
|
Pohlkamp C, Vetro C, Dicker F, Meggendorfer M, Kern W, Haferlach C, Haferlach T. Evidence of clonality in cases of hypereosinophilia of undetermined significance. Leuk Lymphoma 2019; 60:2071-2074. [DOI: 10.1080/10428194.2018.1564825] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
84
|
Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C. Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Br J Haematol 2018; 185:951-954. [PMID: 30460680 DOI: 10.1111/bjh.15653] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
85
|
Stengel A, Jeromin S, Haferlach T, Meggendorfer M, Kern W, Haferlach C. Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease. Haematologica 2018; 104:e187-e190. [PMID: 30409794 DOI: 10.3324/haematol.2018.202952] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
86
|
Urdl K, Weiss S, Karpa A, Perić M, Zikulnig-Rusch E, Brecht M, Kandelbauer A, Müller U, Kern W. Furan-functionalised melamine-formaldehyde particles performing Diels-Alder reactions. Eur Polym J 2018. [DOI: 10.1016/j.eurpolymj.2018.08.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
87
|
Vetro C, Haferlach T, Jeromin S, Stengel A, Zenger M, Nadarajah N, Baer C, Weissmann S, Kern W, Meggendorfer M, Haferlach C. Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses. Br J Haematol 2018; 183:47-59. [PMID: 30022491 DOI: 10.1111/bjh.15498] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 06/07/2018] [Indexed: 01/09/2023]
Abstract
Chronic Lymphocytic Leukaemia (CLL) is a heterogeneous disease with a clinical course dependent on cytogenetic features. However, in 15-20% of cases both chromosome banding and fluorescence in situ hybridisation analyses do not show any kind of abnormality. With the aim to identify dependable molecular prognostic factors in this subgroup, we performed a comprehensive analysis on 171 patients including genomic arrays (comparative genomic hybridisation and single nucleotide polymorphism), immunoglobulin heavy chain variable region genes (IGHV) status, flow cytometry and targeted sequencing. Genomic arrays detected 73 aberrations in 39 patients (23%). Most frequently, patients had 1 aberration (25/171; 15%), while 14 patients (8%) had at least 2 aberrations. IGHV status was unmutated in 53/171 (31%) patients. SF3B1 was the most frequently mutated gene (26/171 patients; 15%), followed by NOTCH1 (15/171; 9%). At univariate analysis, an adverse impact on time to treatment (TTT) was evident for SF3B1 mutations, higher white blood cell count, higher CLL cells percentage by flow cytometry, CD38 positivity, IGHV unmutated status and at least 2 genomic array abnormalities. Of these, SF3B1 mutations, CLL cells percentage, IGHV unmutated status and number of genomic array aberrations maintained their impact in multivariate analysis. In conclusion, by integrating genomic and molecular data, we identified patients at higher risk for treatment need.
Collapse
|
88
|
Nadarajah N, Meggendorfer M, Haferlach C, Kern W, Haferlach T. Abstract 3275: Comparison of somatic variant interpretation results between human experts and automated classification using AMP/ASCO/CAP guidelines. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Evaluating the pathogenicity of a variant is challenging given the plethora of types of genetic evidence that laboratories have to consider. Deciding how to weigh each type of evidence is difficult, and standards are needed. In 2017, AMP/ASCO/CAP released a joint consensus recommendation proposing a four-tiered system to categorize somatic sequence variations based on their clinical significance in cancer diagnosis, prognosis, and/or therapeutic.
Aim: Evaluate how the AMP/ASCO/CAP guidelines compare to an accredited laboratory approach to variant classification and explore the variance in the use and interpretation of the pathogenicity criteria. Identifying disease-contributory variants for various human genetic diseases will greatly improve diagnosis and facilitate development of therapies.
Patients and Methods: 50 cases with myeloid malignancies were selected, analyzed either with a 26 genes myeloid panel (ThunderStorm Target Enrichment library; Raindance, Billerica, MA) or a 63 genes panel (TruSeq Custom Amplicon; Illumina, San Diego, CA). Alignment and Variant calling was performed with JSI SeqPilot (JSI Medisys, Ettenheim, Germany). Molecular geneticists in the lab annotated each variant manually in a 3-tier system (pathogenic, uncertain significance, benign) given the lab's SOP for variant classification. Each variant was checked against the following databases: COSMIC (v76), ClinVar, dbSNP (v147) and IARC TP53 (r17). Population frequency information was extracted from ExAC. Mutation impact prediction was performed using PolyPhen-2, SIFT and VEP.
Results: Among the 50 cases 681 variants were classified during routine workup according to SOPs accredited by EN ISO15189, subsequent to the elimination of sequencing artefacts. 405 were classified as benign, 52 with variant of uncertain significance (VUS) and 224 as pathogenic. Using the computed classification yielded 377 Tier IV (Benign), 184 Tier III (Unknown clinical significance), 93 Tier II (Potential clinical significance) and 27 Tier I (Strong clinical significance). To be able to compare, Tier I and II were binned. In 80% (542/681) of instances both approaches are concordant. 4 variants classified diagnostically discrepant (3 VUS to Tier I/II, 1 benign variant to Tier II) (Table 1). Manual interrogation revealed these were difficult variants with scarce public data and poor concordance of prediction tools.
Conclusion: Systematic evaluation of an automated classification based on AMP/ASCO/CAP with manual curated data found a concordance rate of 80%. The automated approach seems to be more cautious, thus the bias towards more VUS calls, which is preferable to miscalls. The guidelines seem to yield results sufficiently good for clinical use, especially for labs with little experience in variant classification and a big step forward regarding standardization.
Citation Format: Niroshan Nadarajah, Manja Meggendorfer, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach. Comparison of somatic variant interpretation results between human experts and automated classification using AMP/ASCO/CAP guidelines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3275.
Collapse
|
89
|
Reidel V, Kauschinger J, Hauch RT, Müller-Thomas C, Nadarajah N, Burgkart R, Schmidt B, Hempel D, Jacob A, Slotta-Huspenina J, Höckendorf U, Peschel C, Kern W, Haferlach T, Götze KS, Jilg S, Jost PJ. Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. Oncotarget 2018; 9:17270-17281. [PMID: 29707107 PMCID: PMC5915115 DOI: 10.18632/oncotarget.24775] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 02/25/2018] [Indexed: 12/03/2022] Open
Abstract
Somatic mutations in genes such as ASXL1, RUNX1, TP53 or EZH2 adversely affect the outcome of patients with myelodysplastic syndromes (MDS). Since selective BCL-2 inhibition is a promising treatment strategy in hematologic malignancies, we tested the therapeutic impact of ABT-199 on MDS patient samples bearing an adverse mutational profile. By gene expression, we found that the level of pro-apoptotic BIM significantly decreased during MDS disease progression in line with an acquired resistance to cell death. Supporting the potential for ABT-199 treatment in MDS, high-risk MDS patient samples specifically underwent cell death in response to ABT-199 even when harbouring mutations in ASXL1, RUNX1, TP53 or EZH2. ABT-199 effectively targeted the stem- and progenitor compartment in advanced MDS harbouring mutations in ASXL1, RUNX1, TP53 or EZH2 and even proved effective in patients harbouring more than one of the defined high-risk mutations. Moreover, we utilized the protein abundance of BCL-2 family members in primary patient samples using flow cytometry as a biomarker to predict ABT-199 treatment response. Our data demonstrate that ABT-199 effectively induces apoptosis in progenitors of high-risk MDS/sAML despite the presence of adverse genetic mutations supporting the notion that pro-apoptotic intervention will hold broad therapeutic potential in high-risk MDS patients with poor prognosis.
Collapse
|
90
|
Sahin M, Schlögl S, Kalinka G, Wang J, Kaynak B, Mühlbacher I, Ziegler W, Kern W, Grützmacher H. Tailoring the interfaces in glass fiber-reinforced photopolymer composites. POLYMER 2018. [DOI: 10.1016/j.polymer.2018.03.020] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
91
|
Atkin S, Woo V, de la Rosa R, Wilding J, Yamada Y, Birch S, Holst AG, Ahrén B, Kern W. Der Einfluss gastrointestinaler unerwünschter Ereignisse auf die Gewichtsabnahme unter Semaglutid bei Menschen mit Typ 2 Diabetes. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
92
|
Petri KC, Ingwersen SH, Flint A, Zacho J, Overgaard RV, Kern W. Bewertung der Semaglutid-Dosierungen bei Typ 2 Diabetes auf Grundlage von Populationspharmakokinetik und Expositions-Response. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
93
|
Baer C, Pohlkamp C, Haferlach C, Kern W, Haferlach T. Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases. Leukemia 2018; 32:2295-2298. [DOI: 10.1038/s41375-018-0119-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 01/27/2018] [Accepted: 01/31/2018] [Indexed: 12/20/2022]
|
94
|
Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica 2018; 103:e348-e350. [PMID: 29567772 DOI: 10.3324/haematol.2017.187302] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
95
|
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131:1275-1291. [PMID: 29330221 PMCID: PMC5865231 DOI: 10.1182/blood-2017-09-801498] [Citation(s) in RCA: 749] [Impact Index Per Article: 124.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 01/03/2018] [Indexed: 12/13/2022] Open
Abstract
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.
Collapse
|
96
|
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. CYTOMETRY PART B-CLINICAL CYTOMETRY 2018; 94:121-128. [PMID: 29024461 PMCID: PMC5817234 DOI: 10.1002/cyto.b.21595] [Citation(s) in RCA: 104] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 09/26/2017] [Accepted: 10/05/2017] [Indexed: 02/05/2023]
Abstract
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as “required” or “recommended” for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate “required” markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5–20 in 82/150 (55%), and <5 cases per week in 45/150 (30%). The consensus for “required” diagnostic markers included: CD19, CD5, CD20, CD23, Kappa, and Lambda. “Recommended” markers potentially useful for differential diagnosis were: CD43, CD79b, CD81, CD200, CD10, and ROR1. Reproducible criteria for component reagents were assessed retrospectively in 14,643 cases from 13 different centers and showed >97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as “required” for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus “recommended” panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. © 2017 International Clinical Cytometry Society
Collapse
|
97
|
Eibel A, Marx P, Jin H, Tsekmes IA, Mühlbacher I, Smit JJ, Kern W, Wiesbrock F. Enhancement of the Insulation Properties of Poly(2-oxazoline)-co-Polyester Networks by the Addition of Nanofillers. Macromol Rapid Commun 2018; 39:e1700681. [PMID: 29292560 DOI: 10.1002/marc.201700681] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Revised: 11/10/2017] [Indexed: 11/11/2022]
Abstract
Copoly(2-nonyl-2-oxazoline)-stat-poly(2-dec-9'enyl-2-oxazoline)s can be crosslinked by the thiol-ene reaction with glycol dimercaptoacetate. The copoly(2-oxazoline)-stat-copolyester is tested as dielectric for high-voltage applications, either as unfilled resin or as composite with nanoscaled fillers of silica, alumina, and hexagonal boron nitride. During AC voltage tests, all materials have an average breakdown strength of 45-50 kV mm-1 . For DC voltage tests, samples with SiO2 (hBN) have an average breakdown strength of ≈100 (80) kV mm-1 , while the unfilled copoly(2-oxazoline) has an average breakdown strength of ≈60 kV mm-1 . Permittivity measurements at 20 °C and 50 Hz reveal that all nanocomposites are dielectrics (D = 0.06-0.08), while the unfilled copoly(2-oxazoline)s has a high loss factor of D = 8.43. This phenomenon can be retraced to the phase separation in the crosslinked copolymer, the M-OH functionality of silica and alumina particles, and models of polymer-particle interactions such as the Tanaka model, revealing that the nanofillers reduce the interfacial and dipolar polarizability.
Collapse
|
98
|
Sahin M, Krawczyk KK, Roszkowski P, Wang J, Kaynak B, Kern W, Schlögl S, Grützmacher H. Photoactive silica nanoparticles: Influence of surface functionalization on migration and kinetics of radical-induced photopolymerization reactions. Eur Polym J 2018. [DOI: 10.1016/j.eurpolymj.2017.11.046] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
99
|
Hedley B, Cheng G, Luider J, Kern W, Lozanski G, Chin-Yee I, Lowes L, Keeney M, Careaga D, Magari R, Tejidor L. Initial flow cytometric evaluation of the Clearllab lymphoid screen. CYTOMETRY PART B-CLINICAL CYTOMETRY 2017; 94:707-713. [DOI: 10.1002/cyto.b.21603] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 11/16/2017] [Accepted: 11/22/2017] [Indexed: 12/13/2022]
|
100
|
Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerovà K, Haferlach T, Haferlach C. Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML. Leukemia 2017; 32:295-302. [DOI: 10.1038/leu.2017.239] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 06/22/2017] [Accepted: 07/17/2017] [Indexed: 12/23/2022]
|